RNLS and diabetes mellitus: In vivo experiments with NOD mice with long-duration diabetes further suggested that treatment with a monoamine oxidase (MAO) inhibitor, pargyline, mimicked the effects of RNLS deficiency, indicating that MAO-inhibitors targeting RNLS could be a promising approach for further research in T1D drug development (Table 2) (63).